Thyroid-associated ophthalmopathy (TAO) is a multifactorial-mediated autoimmune orbital disease with the highest incidence of orbital disease in adults. Due to the complex clinical manifestations and prolonged course,TAO seriously affect the physical and mental health of patients.The pathogenesis of TAO has not been fully elucidated and the treatment lacks specificity. Therefore, in-depth research on the pathogenesis of TAO is to find effective treatments. In recent years, studies have suggested that there is gut microbiota disorder in TAO, and the risk factors of TAO can promote gut microbiota disorder. Disordered gut microbiota can participate in the occurrence and development of TAO via influencing T cell differentiation, mimicking autoantigens, and influencing host non-coding RNA expression. Modulating the gut microbiota also has therapeutic effects on TAO and is a promising therapeutic approach.
甲状腺相关眼病(thyroid-associated ophthalmopathy，TAO)是一种多因素介导的自身免疫性眼眶病，居成人眼眶疾病发病率首位。其临床表现复杂，病程迁延，严重影响患者的身心健康。TAO的发病机制至今尚未完全明确，治疗上缺乏特异性，对TAO发病机制的深入研究有利于寻找有效的治疗方法。近年的研究表明TAO患者中存在肠道菌群紊乱，TAO的危险因素可促进肠道菌群紊乱。紊乱的肠道菌群可以通过影响T细胞分化，模拟自身抗原和影响宿主非编码RNA表达参与TAO的发生和发展。调节肠道菌群对于TAO有治疗作用，是一种潜在的有前途的治疗方法。.
Keywords: T cells; gut microbiota; thyroid-associated ophthalmopathy; thyrotropin receptor.